
Arthroplasty
Multi-dose oral TXA in total knee arthroplasty reduces blood loss with no increase in complication
Int J Surg. 2019 May;65:45-51.151 patients scheduled for a primary unilateral TKA for osteoarthritis or rheumatoid arthritis were randomized to receive a single 2g dose of oral TXA (2 hrs pre-operation), two doses of oral TXA (2 hrs pre-op, 4 hrs post-op) or multiple doses of oral TXA (2 hrs pre-op, 4, 10 16 hrs post-op). The primary outcome of interest was total blood loss. Results revealed significantly lower amounts of total blood loss in the multi-dose group compared to the single-dose and two-dose groups.
Unlock the full article
Get unlimited access to OrthoEvidence with a free trial
Start TrialCritical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or continue reading this full article
Register Now

Subscribe to "The Pulse"
Evidence-Based Orthopaedics direct to your inbox.